MaaT Pharma SA (EPA:MAAT)
France
· Delayed Price · Currency is EUR 4.160
-0.070 (-1.65%)
At close: Dec 5, 2025
MaaT Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Operating Revenue | 3.92 | 3.22 | 2.23 | 1.43 | 0.97 | - | Upgrade
|
| Revenue | 3.92 | 3.22 | 2.23 | 1.43 | 0.97 | - | Upgrade
|
| Revenue Growth (YoY) | 52.55% | 44.34% | 55.80% | 47.12% | - | - | Upgrade
|
| Cost of Revenue | 1.87 | 1.61 | 0.88 | 0.64 | 0.33 | 0.03 | Upgrade
|
| Gross Profit | 2.06 | 1.6 | 1.35 | 0.79 | 0.64 | -0.03 | Upgrade
|
| Selling, General & Admin | 7.8 | 6.88 | 5.38 | 4.43 | 2.92 | 1.27 | Upgrade
|
| Research & Development | 28.96 | 26.88 | 20.49 | 13.98 | 8.96 | 6.05 | Upgrade
|
| Other Operating Expenses | -4.28 | -3.72 | -4.58 | -4.06 | -2.34 | -2.1 | Upgrade
|
| Operating Expenses | 32.48 | 30.03 | 21.29 | 14.34 | 9.54 | 5.22 | Upgrade
|
| Operating Income | -30.42 | -28.43 | -19.94 | -13.56 | -8.89 | -5.25 | Upgrade
|
| Interest Expense | -1.1 | -0.87 | -0.4 | -0.19 | -0.12 | -0.05 | Upgrade
|
| Interest & Investment Income | - | - | - | 0.05 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.39 | 0.39 | 0.63 | -0.02 | -0.01 | -0 | Upgrade
|
| Pretax Income | -31.13 | -28.9 | -19.72 | -13.71 | -9.02 | -5.3 | Upgrade
|
| Net Income | -31.13 | -28.9 | -19.72 | -13.71 | -9.02 | -5.3 | Upgrade
|
| Net Income to Common | -31.13 | -28.9 | -19.72 | -13.71 | -9.02 | -5.3 | Upgrade
|
| Shares Outstanding (Basic) | 15 | 13 | 11 | 10 | 2 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 13 | 11 | 10 | 2 | 1 | Upgrade
|
| Shares Change (YoY) | 22.07% | 14.95% | 14.89% | 307.65% | 135.06% | - | Upgrade
|
| EPS (Basic) | -2.14 | -2.21 | -1.73 | -1.39 | -3.72 | -5.14 | Upgrade
|
| EPS (Diluted) | -2.15 | -2.21 | -1.73 | -1.39 | -3.72 | -5.14 | Upgrade
|
| Free Cash Flow | -25.45 | -22.79 | -19.76 | -13.27 | -8.17 | -6.16 | Upgrade
|
| Free Cash Flow Per Share | -1.75 | -1.75 | -1.74 | -1.34 | -3.37 | -5.97 | Upgrade
|
| Gross Margin | 52.40% | 49.81% | 60.59% | 55.11% | 66.05% | - | Upgrade
|
| Operating Margin | -775.65% | -883.95% | -895.11% | -947.97% | -914.92% | - | Upgrade
|
| Profit Margin | -793.80% | -898.76% | -884.96% | -958.95% | -927.88% | - | Upgrade
|
| Free Cash Flow Margin | -648.96% | -708.77% | -887.03% | -927.76% | -840.23% | - | Upgrade
|
| EBITDA | -30.21 | -28.2 | -19.74 | -13.32 | -8.71 | -5.15 | Upgrade
|
| D&A For EBITDA | 0.21 | 0.23 | 0.2 | 0.24 | 0.18 | 0.1 | Upgrade
|
| EBIT | -30.42 | -28.43 | -19.94 | -13.56 | -8.89 | -5.25 | Upgrade
|
| Advertising Expenses | - | 0.25 | 0.24 | 0.19 | 0.15 | 0.1 | Upgrade
|
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.